# Talking Medicines moves to capture pharma demand for better patient intelligence

- Link: https://www.directorstalkinterviews.com/talking-medicines-moves-to-capture-pharma-demand-for-better-patient-intelligence/4121262816
- Published: 2026-09-21T14:37:00+01:00
- Author: Amilia Stone

Proposed changes to US pharmaceutical advertising rules could strengthen demand 
for the type of patient intelligence provided by Talking Medicines.

The US Food and Drug Administration added a proposal on transparency in direct-to-
consumer advertising to its Unified Agenda in July 2026. At the same time, US Health
and Human Services Secretary Robert F. Kennedy Jr. indicated that the existing “
adequate provision” framework could be reviewed. Any tightening of the rules would
put more pressure on pharmaceutical companies to get consumer-facing messaging right
before campaigns are launched.

Talking Medicines DrugVoice platform uses artificial intelligence to analyse real-
world healthcare conversations and identify what patients are saying about treatments,
symptoms, unmet needs, misconceptions and concerns.

If pharmaceutical companies face stricter requirements around how products are presented
to patients, they may need better evidence on what those patients understand, question
and respond to before advertising is created. DrugVoice is designed to provide that
information earlier in the process.

Instead of relying mainly on campaign performance data after launch, Talking Medicines
is targeting the planning stage. Its technology is intended to help pharmaceutical
brands and agencies shape messaging around actual patient conversations rather than
assumptions.

Poorly judged messaging can create compliance risk, weaken campaign effectiveness
and force companies to make changes after money has already been committed. Better
intelligence at the start of the process can help reduce those risks.

Talking Medicines also combines Patient Intelligence with Healthcare Professional
Intelligence. Patient data can show how people talk about treatments, what concerns
them and where misunderstandings exist. Healthcare professional data can provide
insight into prescribing priorities, clinical engagement and treatment adoption.

Bringing those perspectives together can help pharmaceutical companies make more
informed decisions before committing to campaign strategy.

_**[Tern plc](https://www.directorstalkinterviews.com/company/tern-plc/tern.l) **(
[LON:TERN](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)) backs
exciting, high growth IoT innovators in Europe. They provide support and create 
a genuinely collaborative environment for talented, well-motivated teams._

Share on:
